Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $6.04 Million - $8.53 Million
-311,217 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$25.02 - $54.99 $10.2 Million - $22.5 Million
-409,285 Reduced 56.81%
311,217 $8.03 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $49.3 Million - $68.2 Million
-1,201,061 Reduced 62.5%
720,502 $38.5 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $4.25 Million - $6.64 Million
116,570 Added 6.46%
1,921,563 $79.3 Million
Q2 2020

Aug 14, 2020

SELL
$39.26 - $52.73 $7.49 Million - $10.1 Million
-190,754 Reduced 9.56%
1,804,993 $87.5 Million
Q1 2020

May 15, 2020

BUY
$31.65 - $46.87 $23.6 Million - $35 Million
745,747 Added 59.66%
1,995,747 $84.3 Million
Q4 2019

Feb 14, 2020

SELL
$36.21 - $51.4 $34.1 Million - $48.4 Million
-940,742 Reduced 42.94%
1,250,000 $53.5 Million
Q3 2019

Nov 15, 2019

BUY
$22.22 - $44.01 $15.3 Million - $30.4 Million
690,742 Added 46.05%
2,190,742 $78.8 Million
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $11.7 Million - $14.1 Million
-500,000 Reduced 25.0%
1,500,000 $0
Q1 2019

May 14, 2019

SELL
$16.17 - $27.38 $12.2 Million - $20.6 Million
-752,256 Reduced 27.33%
2,000,000 $53.7 Million
Q4 2018

Feb 15, 2019

BUY
$14.32 - $22.92 $22.3 Million - $35.7 Million
1,556,158 Added 130.1%
2,752,256 $44.5 Million
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $10.5 Million - $17.5 Million
-803,902 Reduced 40.2%
1,196,098 $24.8 Million
Q2 2018

Aug 14, 2018

BUY
$15.07 - $22.34 $30.1 Million - $44.7 Million
2,000,000 New
2,000,000 $30.5 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.71B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.